These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32317663)

  • 21. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
    Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.
    Foo J; Michor F
    PLoS Comput Biol; 2009 Nov; 5(11):e1000557. PubMed ID: 19893626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.
    Schueler J; Tschuch C; Klingner K; Bug D; Peille AL; de Koning L; Oswald E; Klett H; Sommergruber W
    Cells; 2019 Jul; 8(7):. PubMed ID: 31323891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced resistance evolution necessitates less aggressive treatment.
    Kuosmanen T; Cairns J; Noble R; Beerenwinkel N; Mononen T; Mustonen V
    PLoS Comput Biol; 2021 Sep; 17(9):e1009418. PubMed ID: 34555024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
    Xiao Z; Li M; Zhang X; Rong X; Xu H
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.
    Wang Y; Lian YM; Ge CY
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5831-5839. PubMed ID: 31298334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells.
    Cui Z; Liu Z; Zeng J; Zhang S; Chen L; Zhang G; Xu W; Song L; Guo X
    Life Sci; 2019 May; 224():23-32. PubMed ID: 30902544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
    Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
    Gong J; He L; Ma J; Zhang J; Wang L; Wang J
    J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells.
    Liao CH; Tzeng YT; Lai GM; Chang CL; Hu MH; Tsai WL; Liu YR; Hsia S; Chuang SE; Chiou TJ; Wang LM; Whang-Peng J; Yao CJ
    Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32751169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial designs for evaluating and exploiting cancer evolution.
    Ingles Garces AH; Porta N; Graham TA; Banerji U
    Cancer Treat Rev; 2023 Jul; 118():102583. PubMed ID: 37331179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer.
    Yu C; Li B; Wang J; Zhang Z; Li S; Lei S; Wang Q
    Ann Clin Lab Sci; 2021 Sep; 51(5):625-637. PubMed ID: 34686504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 39. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
    Jin S; He J; Li J; Guo R; Shu Y; Liu P
    Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.